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1. Introduction 
Upper gastrointestinal tract integrity is dependent upon the delicate balance between 
naturally occurring protective factors as mucus or prostaglandins and damaging factors as 
hydrochloric acid present normally in the digestive juices. An imbalance causes peptic ulcer 
formation and destruction of gastrointestinal tract mucosal lining. Ulcer may develop in the 
esophagus, stomach, duodenum or other areas of elementary canal. In women, gastric ulcers 
are more common than duodenal ulcers, while in men the opposite is true. 
The ulcer irritates surrounding nerves and causes a considerable amount of pain. 
Obstruction of the gastrointestinal tract may occur as a result of spasm or edema in the 
affected area. The ulcer may also cause the erosion of major blood vessels leading to 
hemorrhage, hematemesis and/or melena. Deep erosion of the wall of the stomach or the 
intestine may cause perforation and peritonitis, which is a life-threatening condition 
needing emergency intervention. Duodenal ulcers are almost always benign but stomach 
ulcers may turn malignant. Although mortality rates of peptic ulcer are low, the high 
prevalence of the disease, the accompanying pain and its complications are very costly. 
The ongoing rapidly expanding research in this field provides evidence suggesting that, 
with therapeutic and dietetic advances, gastric ulcer may become preventable within the 
next decade. This could be achieved by strengthening the defense mechanisms of the gastric 
mucosa and, in parallel, limiting the aggression of predisposing factors causing gastric 
ulceration. The defenses of the gastric mucosa are incredibly efficient under normal 
mechanical, thermal or chemical conditions. These defenses can endure insults from food, 
gastric enzymes and acid secretion. Even trauma caused by a biopsy wound is dealt with 
and can heal relatively fast, within hours. 
However, under certain condition, some risk factors may contribute to mucosal injury and 
initiation of gastric ulcer, as psychological stress, increased hydrochloric acid secretion, 
Zollinger Ellison syndrome and family history of gastric ulcer. Conditions associated with 
increased risk of gastric ulcer include also chronic disorders as liver cirrhosis, chronic 
obstructive pulmonary disease, renal failure, organ transplantation and rheumatoid 
arthritis. In addition, severe physical stress as in case of burns, major surgery or head 
trauma may also contribute as risk factors. 
Avoidable risk factors that may predispose to gastric ulcer include smoking, high 
consumption of alcohol and intake of some medications as non-steroidal anti-inflammatory 
drugs. Some factors are thought to aggravate already established gastric ulcer, but are no 
longer considered risk factors predisposing to it, as ingestion of too hot or cold foods or 
drinks, eating spicy food and intake of caffeine. The key cause of gastric ulcer is now known 
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to be the infection by a certain gram negative bacterium called Helicobacter pylori. 
Although the mechanism by which the infection by this bacterium leads to ulcer formation 
is not yet fully understood, it is believed that infection decreases the normal immunity of the 
gastrointestinal tract wall, which in turn weakens the mucosa and makes it vulnerable to 
ulceration under the acidic effect of gastric secretions. 
Avoiding risk factors is the first line in prevention of gastric ulcer. Smoking cessation and 
alcoholic consumption minimization may help in reducing the risk of ulcer formation. In 
addition, sanitary food and drinking habits to avoid infection with Helicobacter pylori may 
help in ameliorating the initiation of gastric ulcer and its recurrence. Therapeutic 
interventions to eradicate Helicobacter pylori can also prevent ulcer formation and its 
transformation into gastric cancer, one of the major complications of chronic gastric ulcer. 
Avoiding unnecessary intake of ulcer-inducing over-the-counter medications may help in 
reducing the prevalence of gastric ulcers. 
Active therapeutic measures can aid in preventing gastric ulcers in predisposed groups and 
in patients with healed gastric ulcer to avoid its recurrence. Such therapeutic interventions 
may be of natural herbal sources or medicinal drugs. A number of traditional anti-ulcer 
drugs may be used in prevention as well as in treatment of gastric ulcer. Proton pump 
inhibitors, histamine H2 receptor antagonists and mucosal protective agents can thus all be 
used as protective drugs against initiation of gastric ulcer in predisposed groups as well as 
prevention of remittent attacks. Recent investigations showed that a number of drugs, other 
than traditional anti-ulcer medications, can help in prevention of gastric ulcer formation. 
Herbal compounds can also protect against gastric ulcer and they have the advantage of 
being safer, cheaper and usually having limited, if any, side effects. 
In this chapter, a collection of updated recent information published about gastric ulcer 
protection is gathered. Information in this chapter can be considered as guidelines for 
clinical practice to direct medical personnel perception to preferred approaches to prevent 
gastric ulcer as established by scientifically valid research. Making such information 
available may also increase public awareness of preventive means of gastric ulcer, which 
may aid in decreasing the suffering of a large number of populations exposed to the disease 
worldwide. 
2. Avoidance of gastric ulcer risk factors 
The best and cheapest method to prevent gastric ulceration is the avoidance of risk factors 
resulting in the occurrence of the disease. Avoiding Helicobacter pylori infection, alternation 
of life style and substitution of ulcer-inducing medications with less harmful drugs can thus 
contribute largely to prevent gastric ulcer disease (Fig. 1). Unfortunately, some risk factors are 
unavoidable. One of the strongest risk factors for initiation of a gastric ulcer is the presence of 
prior ulcer disease with history of ulcer complications as previous perforation or hemorrhage. 
Zollinger-Ellison Syndrome is another unavoidable cause of gastric ulceration. In this 
syndrome, tumors producing gastrin hormone (gastrinomas) in the pancreas and 
duodenum stimulate gastric acid secretion. The large amounts of excess acid produced 
cause gastro-intestinal ulceration. Ulcers may form in the stomach, duodenum, jejunum or 
other atypical sites in the elementary tract. The incidence of this disease is less than 1% and 
men are more affected than women. The syndrome is suspected in patients with ulcers who 
are not infected with Helicobacter pylori and who have no history of non-steroidal anti-
inflammatory drugs use. Diagnosis is confirmed by measurement of serum gastrin hormone 
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Fig. 1. Methods of prevention of gastric ulcer: Avoiding risk factors as Helicobacter pylori, 
drug-induced ulcer by medications as non-steroidal anti-inflammatory drugs and 
performance of life style changes. 
levels which is usually very high, reaching above 1000 pg/ml (normal level is < 100 pg/ml). 
Diarrhea may occur before ulcer symptoms. Gastro-esophageal reflux disease may occur 
and its complications may include narrowing due to strictures of the esophagus. Ulcers 
associated with this syndrome are usually persistent and difficult to treat. In the past, 
removing the stomach was the only option for treatment. Nowadays, treatment includes 
removing the tumors only and therapeutic suppression of acid secretion. 
Other unavoidable factors associated with higher incidence of gastric ulcer include sex, as 
there is higher prevalence of the disease among women then men. People over age 60 years 
old are also more prone to gastric ulcer disease. In addition, ethnic backgrounds as African-
Americans or Hispanics have 2-fold higher risk in developing gastric ulcer. Furthermore, 
patients suffering from other diseases as congestive heart failure have higher incidence of 
having gastric ulcer as well. Type O blood group has also been associated with increased 
incidence of the disease. Genetics is another unavoidable risk factor of gastric ulcer. 
Pepsinogen C gene polymorphism, for example, is significantly associated with 
development of gastric ulcer (Sun et al., 2009). Other relatively rarer predisposing factors to 
development of gastric ulcer includes Crohn’s disease of the stomach, eosinophilic gastritis, 
systemic mastocytosis, radiation damage and viral infections by cytomegalovirus or herpes 
simplex (Malfertheiner et al., 2009). 
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2.1 Helicobacter pylori as a risk factor for gastric ulcer 
Infection with Helicobacter pylori is the most well-defined risk factor for the development of 
peptic ulcers. The two Australian scientists who identified Helicobacter pylori as the main 
cause of stomach ulcers in 1982 were awarded the Nobel Prize in Medicine in 2005 for this 
discovery. Helicobacter pylori bacteria are found in about 50% of people with gastric ulcer 
disease. Inflammation of the stomach and stomach ulcers result from the infection by these 
bacteria, as their corkscrew shape enables them to penetrate the mucus layer of the stomach so 
that they can attach themselves to the lining. The surfaces of the cells lining the stomach 
contain a protein, called decay-accelerating factor, which acts as a receptor for the bacterium. 
Helicobacter pylori can survive in the highly acidic medium of the stomach by producing 
urease, an enzyme that generates ammonia to neutralize the acid. These bacteria then 
produce a number of toxins causing inflammation and damage to the stomach, leading to 
ulcers especially in predisposed individuals. The bacteria also alter certain immune factors 
that allow them to evade detection by the immune system and cause persistent 
inflammation. Even if ulcers do not develop, the bacterium is considered to be a major cause 
of active chronic inflammation in the stomach (gastritis). Helicobacter pylori together with 
unavoidable risk factors as genetics and concomitant diseases may contribute in gastric 
ulcer formation and the subsequent metaplasia and dysplasia leading to gastric cancer (Fig. 
2). Avoidance of risk factors, therapeutic intervention and some protective herbs can be 
employed to prevent the initiation of this sequence. 
 
Normal
H. pylori
Drugs
Genetics
Other factors
Gastric Ulcer
Metaplasia
Dysplasia
Gastric Cancer
Prevention of Risk Factors
Eradication of H. pylori
Avoid drug-induced ulcer
Changing life style
Therapeutic Prevention
Protective Herbs
 
Fig. 2. Prevention of gastric ulcer formation is a step in preventing the development of 
gastric cancer.  
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Less than 15% of people infected with Helicobacter pylori develop gastric ulcer. Factors that 
trigger gastric ulcers in Helicobacter pylori carriers include genetic factors, which explain 
the higher incidence of development of ulcers in certain ethnicity. Another factor is 
abnormal immune response, which allows the bacteria to injure the stomach lining. Lifestyle 
factors as chronic stress, drinking coffee and smoking were long believed to be primary 
causes of gastric ulcer; it is now thought that they only increase susceptibility to ulcers in 
some Helicobacter pylori carriers. Interrupted sleep may be another trigger as people who 
work at night shifts have a significantly higher incidence of ulcers than day workers. 
Frequent interruption of sleep is thought to weaken the immune system's ability to protect 
against harmful bacterial substances. 
Using certain medications as non-steroidal anti-inflammatory drugs or corticosteroids may 
contribute to higher infection rates of Helicobacter pylori. Patients with prior gastric ulcer, 
Zollinger-Ellison syndrome, congenital stomach malformations, malignant diseases such as 
mastocytosis and basophilic leukemia, head trauma, severe traumatic injuries, burns, 
radiation, or recently had major surgery are also more prone to Helicobacter pylori 
infection. Increased risk of Helicobacter pylori infection is seen among people who live in 
crowded places with unsanitary conditions. Some genetic predispositions for Helicobacter 
pylori infection cure rate may exist. One example is cytochrome P450-2C19 polymorphism 
that seems to predict the cure of Helicobacter pylori infection and predisposition to gastric 
ulcer (Lay and Lin, 2010). Another example is cytokine genes polymorphism that was 
significantly associated with persistent infection (Abdiev et al., 2010). Polymorphism of 
multidrug resistance protein 1 also was reported to influence Helicobacter pylori-induced 
gastric inflammation (Tahara et al., 2011). Such genetic predisposition gives us hope that the 
infection predisposing to peptic ulcer and gastric cancer may some day be a target for 
preventive gene therapy in the near future.  
Therapeutic interventions to eradicate Helicobacter pylori are needed to prevent ulcer 
formation and its transformation to gastric cancer, one of the major complications of chronic 
gastric ulcer. Helicobacter pylori eradication therapy comprises a combination of two or 
more drugs including antimicrobials, proton pump inhibitors and gastro-protective agents. 
Several eradication methods were suggested. Dual eradication therapy using proton pump 
inhibitor with amoxicillin was tried (Graham et al., 2010). Triple eradication therapy 
employing 2 antimicrobials together with proton pump inhibitor also showed some success, 
but not enough to be considered first-line treatment. Quadruple Helicobacter pylori 
eradication was also successfully tried and consisted of 2 antimicrobials, proton pump 
inhibitor and the gastro-protective agent colloidal bismuth subcitrate (Zheng et al., 2010). 
Nowadays, the first line of Helicobacter pylori eradication therapy is a regimen of 7 or 14 
days consisting of a proton pump inhibitor as omeprazole (20 mg 12 hourly), in combination 
with clarithromycin (500 mg 12 hourly) and metronidazole (400 mg 12 hourly). A second 
regimen that is equally effective is by using omeprazole as previously mentioned, together 
with less dose of clarithromycin (250 mg 12 hourly) and substituting metronidazole with 
amoxicillin (1 g 12 hourly). Omeprazole can be replaced with other proton pump inhibitors. 
Despite that the prevalence of Helicobacter pylori is decreasing in developed countries, as a 
result of improvements in living standards and hygiene, Helicobacter pylori is still a 
common cause of gastric ulcer in developing countries. Attempts to develop effective 
vaccination against this bacterium reached phase I and II clinical trials, and may present 
effective preventive strategy in preventing gastric ulcer formation and, more importantly, 
preventing gastric cancer in the future (Majumdar et al., 2011).  
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2.2 Avoidance of drug-induced gastric ulcers 
Patients receiving medications as non-steroidal anti-inflammatory drugs, the anticoagulant 
drug warfarin, corticosteroids or the anti-osteoporotic drug alendronate may be more prone 
to gastric ulcer. Non-steroidal anti-inflammatory drugs are valuable therapeutics that act not 
only as anti-inflammatory, but also as analgesics and antipyretics. They are used in a wide 
variety of clinical scenarios, including arthritis and other musculoskeletal disorders. 
Unfortunately, their use has been limited by their gastric ulcer-inducing effects. Nearly 25 % 
of chronic users of these drugs develop gastric ulcer disease (Lanza et al., 2009). 
The rate of non-steroidal anti-inflammatory drugs-induced gastric ulcers is increasing, as 
more people are taking these drugs regularly as over-the-counter self-therapy. In general, 
the possibility of gastric ulcer initiation of a non-steroidal anti-inflammatory drug with non-
selective cyclooxygenase inhibition actions correlates with its anti-inflammatory activity. 
Non-steroidal anti-inflammatory drugs with a high analgesic effect at doses with low anti-
inflammatory activity, such as ibuprofen, are less ulcerogenic than those that have adequate 
analgesic effects only at doses with high anti-inflammatory activity, as in case of piroxicam. 
Ibuprofen appears safer compared to other members of this drug group in part because it is 
frequently prescribed for short durations in a low dose to control temporary mild painful 
conditions. However, when full anti-inflammatory doses of ibuprofen are given, the risk of 
gastric ulceration with ibuprofen is comparable with other non-steroidal anti-inflammatory 
drugs. 
One member of this group is indomethacin, which is a frequently clinically used and is 
also applied to induce experimental animal model of acute gastric ulcer. Indomethacin 
induces gastric injury by suppressing the formation of prostaglandins, which control 
many of the components of mucosal defense system, as they stimulate mucus and 
bicarbonate secretion, elevate mucosal blood flow, increase the resistance of epithelial 
cells to injury induced by cytotoxins and suppress the recruitment of leucocytes into the 
mucosa. Prostaglandins can also inhibit the release of a number of inflammatory 
mediators, such as tumor necrosis factor-ǂ from macrophages and interleukin-8 from 
neutrophils. Tumor necrosis factor-ǂ promotes gastric epithelial cell apoptosis and 
triggers activation of adhesion molecules and leucocyte recruitment, leading to 
microvascular perturbations. Other mechanisms by which indomethacin induce gastric 
injury involves gastric hypermotility and the increased production of reactive oxygen 
species, as well as lipid peroxidation (Morsy et al., 2010). 
Physicians prescribing these drugs face two problems; one problem is identification of high-
risk patients and the second is selection of appropriate strategies to prevent gastric ulcer. 
Risk factors of these drugs-induced gastric ulcers include older age, concomitant use of 
anticoagulants, corticosteroids, other non-steroidal anti-inflammatory drugs including low-
dose aspirin, and chronic debilitating disorders, especially cardiovascular diseases. 
Helicobacter pylori infection increases the risk of this drugs-induced gastric ulcer. 
Eradication of Helicobacter pylori infection, if present, in patients requiring long-term 
therapy by these drugs is recommended. 
Patients who require long-term non-steroidal anti-inflammatory drug therapy can reduce 
their risk of inducing ulcers by concomitantly taking conventional anti-ulcer therapy. Proton 
pump inhibitors and/or histamine H2 receptor antagonists can significantly reduce these 
drug-induced gastric ulcers. The synthetic prostaglandin E1 analog, misoprostol, is also very 
effective in preventing the development of gastric ulcers in patients taking these 
medications. Unfortunately, its use is limited by its gastrointestinal adverse effects. 
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Avoiding unnecessary intake of ulcer-inducing over-the-counter medications may help in 
reducing the prevalence of gastric ulcers. When it is mandatory to use such therapeutics, 
their replacement with less irritating drugs may reduce ulcer formation. Non-steroidal anti-
inflammatory drugs which are selective cyclooxygenase-2 inhibitors show similar anti-
inflammatory, analgesic and antipyretic efficacy compared to non-selective inhibitors. 
However, these selective drugs are associated with lower incidence of gastric ulcers. 
Unfortunately, there use is limited due to their association with myocardial infarction and 
thrombosis. Unexpectedly, experiments using cyclooxygenase-1 knockout mice showed that 
these animals do not develop gastric ulceration at higher rate and have some reduced 
inflammatory response. 
Some studies tried to find a safer replacement for non-steroidal anti-inflammatory drugs as 
regards their gastric ulcerogenic effect. In one study, a safer anti-inflammatory drug as 
regards its gastric toxicity was developed (Shoman et al., 2009). A number of nitric oxide 
donating pyrazoline derivatives were synthesized and they showed equivalent anti-
inflammatory effect to the anti-inflammatory drug indomethacin, with significantly less 
development of gastric ulceration. Other similar trials have been made by other 
investigators, for example testing the effect of cyclodextrin combination with non-steroidal 
anti-inflammatory drugs on gastric ulcer formation which resulted in gastro-protective 
effect (Alsarra et al., 2010). 
2.3 Life style risk factors 
Several studies implied that modulating life style factors as dietary factors, controlling 
stress, reducing smoking and alcohol intake may directly prevent the initiation of gastric 
ulcers, especially in predisposed people. Some even suggested certain physical exercises to 
reduce the risk of ulcer formation or recurrence. Such exercises were seen to directly 
improve psychological and cardiovascular conditions and thus may be indirectly related to 
decreasing gastric ulcer development.  
2.3.1 Diet 
Diet rich in fibers may decrease the risk of developing gastric ulcers by about 50%. Fiber 
found in fruits and vegetables is particularly protective, as vitamin A contained in many of 
these foods may increase the benefit. Milk, previously thought to aid in decreasing ulcer 
symptoms, actually encourages the production of acid in the stomach, although moderate 
amounts (2-3 cups/day) appear to do no harm. However, yogurt may protect against gastric 
ulcer, as it contains probiotics. Coffee (caffeinated and decaffeinated), soft drinks and fruit 
juices with citric acid increase stomach acid production. Although no studies have proven 
that any of these drinks contribute to ulcers, consuming more than 3 cups of coffee per day 
may increase susceptibility to Helicobacter pylori infection (University of Maryland Medical 
Center website). 
Studies conducted on spices and peppers have yielded conflicting results. In general, these 
substances should be used moderately, and should be avoided if they irritate the stomach. 
Some studies suggest that high amounts of garlic may have some protective properties 
against stomach cancer, although a recent study concluded that garlic offered no benefits 
against Helicobacter pylori and, in large amounts, can cause considerable gastrointestinal 
distress. Studies have shown that phenolic compounds in virgin olive oil may be effective 
against Helicobacter pylori infection. Although no vitamins have been shown to protect 
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against Helicobacter pylori-induced ulcers, Helicobacter pylori appears to impair the 
absorption of vitamin C, which may play a role in the higher risk of stomach cancer. 
2.3.2 Psychological factors: stress 
As a body response to stress, many diseases may develop. There is debate as to whether 
psychological stress can influence the development of gastric ulcers. Some studies still 
suggest that stress may predispose a person to ulcers or prevent existing ulcers from 
healing. Some even believe that the relationship between stress and ulcers is so strong that 
people with ulcers should be treated for psychological conditions. Stress causes the 
digestive tract to slow down and more gastric acid is allowed to accumulate in the stomach. 
Increased stomach acidity may predispose to or aggravate an already present ulcer. Stress 
can also cause change in appetite, leading to over-eating or lack of appetite. Overeating 
causes the stomach to produce more acid while lack of appetite will subject the stomach 
mucosa to the acid produced in an empty stomach. Although psychological stress is no 
longer considered a direct cause of ulcers, it surely can delay the healing and aggravate 
already existing gastric ulcers. Physical stress, however, is definitely a risk factor for 
developing gastric ulcers, as in patients with injuries such as severe burns or patients 
undergoing major surgeries. 
2.3.3 Smoking 
Cigarette smoking appears to be a risk factor for the development and recurrence of gastric 
ulcer. The incidence of gastric ulcer is higher among smokers than non-smokers. Compared 
with non-smokers, people who smoke cigarettes are twice as likely to develop gastric ulcer. 
Smoking may lead to initiation of ulceration, slow ulcer healing and an increased risk of 
gastric ulcer recurrence. Smoking may have an inconsistent effect on gastric acid secretion; 
however it reduces prostaglandin and bicarbonate production, reduces mucosal blood flow, 
interferes with the action of histamine H2 receptor antagonists and accelerates gastric 
emptying of liquids. Cessation of smoking or reducing it is usually associated with the 
prompt relief of already existing gastric ulcer symptoms. 
2.3.4 Excess alcohol intake 
Alcohol increases the production of acid in the stomach, which may irritate an existing 
ulcer. Alcohol also relaxes the lower esophageal sphincter, allowing stomach contents to 
reflux back up into the esophagus, increasing the discomfort associated with gastric ulcer. 
Patients suffering of gastric ulcer should, thus, avoid taking alcohol. People predisposed to 
gastric ulcer may dilute alcoholic beverages to reduce their concentration, restrict the 
number of drinks to one or two a day, replace red wine with white wine of less toxic 
content, or better, have drinks which are non-alcoholic. 
3. Endogenous protection against gastric ulcer 
Astonishingly, despite of the presence of one or more risk factors as smoking, alcohol intake, 
non-steroidal anti-inflammatory drugs consumption and/or Helicobacter pylori infection, 
some people still do not develop gastric ulcer. For example, non-steroidal anti-inflammatory 
drugs induce clinically significant gastric ulceration in 17% of patients receiving these drugs. 
This is due to the strong natural endogenous gastric cyto-protection that spares the vast 
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majority of patients at risk. Gastric mucosal barrier together with endogenous mediators 
comprise a strong defense mechanism against gastric ulceration. Understanding these 
naturally occurring defense mechanisms is crucial to try to enhance them to prevent gastric 
damage and ulceration in more vulnerable patients.  
3.1 Physiological gastric mucosal barrier 
The gastric mucosal barrier is considered the main defense system against gastric ulcer 
formation. Several luminal factors contribute to this barrier (Fig. 3). These factors include 
secretion of bicarbonates, mucus, phospholipids and immunoglobulins. The gastric 
epithelial barrier also represents part of the defense system that is remarkably resistant to 
acids or irritants and has the capability of rapid repair. The mucosal microcirculation, 
together with sensory innervations, harmonically defends the mucosal barrier. Sensing 
acidic diffusion into the gastric mucosa results in neural system-mediated induced 
endogenous mediator release and hormonal responses leading to increase in mucosal blood 
flow, which is a critical step in preventing damage and facilitating repair of gastric mucosa. 
The mucosal immune system represents another gastric mucosal protective method. Mast 
cells and macrophage generate immune signals of inflammatory response that contributes to 
prevention of gastric damage. 
3.1.1 Luminal gastric protection 
The mucus-bicarbonate-phospholipid barrier comprises the first line of mucosal defense 
mechanism. This barrier is formed of mucus, bicarbonate and phospholipids. Mucus 
presents a layer that contains secreted bicarbonate and surfactant phospholipids. Mucus that 
acts as a physical barrier against luminal digestive enzymes, bicarbonate that maintains an 
almost neutral pH at the epithelial surface, together with phospholipids of high 
hydrophobic properties can naturally protect against mucosal damage. Disruption of this 
mucus-bicarbonate-phospholipid barrier by ulcerogenic substances, as bile salts or non-
steroidal anti-inflammatory drugs causes elevated diffusion of acid into the mucosa and 
mucosal damage (Allen and Flemstrom, 2005). Helicobacter pylori release phospholipase 
enzymes and ammonium ions that can reduce the strength of this single and only barrier 
existing between the epithelium and the lumen. Other protective mechanisms may then 
interfere to protect against this bacterial induced injury. 
3.1.2 Gastric epithelial barrier  
Mucosal surface is formed of a continuous layer of surface epithelial cells that secrete 
components of the mucus barrier as well as endogenous protective mediators as 
prostaglandins, heat shock proteins and cathelicidins (see below; section 3.2). These surface 
epithelial cells form a physical barrier preventing back-diffusion of gastric acid and 
digestive enzymes. Basolateral membrane of epithelial parietal cells, that secrete 
hydrochloric acid in high concentrations into the lumen of the stomach, contains 
transporters responsible for maintaining intracellular homeostasis. These transporters efflux 
large amounts of bicarbonate to prevent cell alkalinization. The effluxed bicarbonate, known 
as alkaline tide, is an integral constituent of mucus-bicarbonate barrier (Tulassay and 
Herszenyi, 2010). Continuous and rapid cell renewal enhances the resistance of epithelial 
barrier to damage. Mucosal progenitor cells in gastric epithelium promote cell renewal by 
continuously replacing surface cells that undergo apoptosis. Proliferation of progenitor cells 
is controlled by endogenous growth factors’ mediators. 
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Fig. 3. Physiological gastric mucosal barrier. It is composed mainly of protective luminal 
mucus layer, gastric epithelial barrier, immune cells, gastric microcirculation and sensory 
gastric innervation. 
3.1.3 Mucosal microcirculation 
Mucosal ischemia triggers gastric ulcer by inducing tissue necrosis, free radical formation 
and cessation of nutrient transport, all resulting from vascular and microvascular injury 
such as thrombi, constriction or other occlusions. Mucosal blood flow thus provides gastric 
lining with adequate vascular perfusion that prevents epithelial damage from progressing to 
necrosis of deeper layers of the mucosa. Increase in mucosal blood flow occurs as a response 
to gastric mucosal exposure to an irritant or when acid back-diffusion occurs. Potent 
vasodilators such as nitric oxide and prostaglandin I2 generated by endothelial cells protect 
the gastric mucosa against injury and damaging action of vasoconstrictors such as 
leukotriene C4, thromboxane A2 and endothelin. These potent vasodilators prevent platelet 
and leucocyte adherence to endothelial cells, maintain the integrity of the gastric epithelium 
and the mucus barrier and protect the gastrointestinal tract by inhibiting gastric acid 
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secretion from parietal cells. Endogenous mediators that affect mucosal microcirculation as 
nitric oxide and hydrogen sulfide are further discussed below (section 3.2). 
3.1.4 Gastric sensory innervation 
Gastric mucosal defense is also regulated by the central nervous system innervation. Gastric 
mucosa and submucosal vessels are innervated by primary afferent sensory neurons. When 
gastric mucosa gets exposed to damage by gastric acid or other irritating chemicals, afferent 
neurons are activated and directly start controlling the tone of the submucosal arterioles, 
which regulate mucosal blood flow. When sensory afferent nerves of the superficial mucosa 
detect gastric acid, they respond by releasing neurotransmitters as substance P and 
calcitonin gene-related peptide. These mediators cause relaxation of smooth muscle 
surrounding gastric mucosal arterioles, resulting in an elevation of mucosal blood flow. In 
addition, vagal activation increase mucus secretion, while nervous response to stress control 
central corticotropin-releasing factor signaling pathways. Furthermore, the transient 
receptor potential vanilloid 1 agonists are effective in protecting gastric mucosa against 
various experimentally induced ulcer models (Morsy and Fouad, 2008). 
3.1.5 Mucosal immune system 
The mucosal immune system is a key factor of mucosal defense against exogenous and 
endogenous irritants. Impairment of this immune system can lead to mucosal injury and to 
impairment of endogenous cyto-protective repair mechanisms. The mucosal immune 
system is coordinated by innate and adaptive immune response regulated by several 
mediators released from immuno-regulating cells. Neutrophils and macrophages infiltrate 
into the gastric mucosa as a response to Helicobacter pylori infection. These cells release 
lysosomal enzymes, leukotrienes and reactive oxygen species which impairs mucosal 
defense and drives the immunopathogenetic process of ulcerogenesis. T and B lymphocytes 
activated by bacterial antigens and pro-inflammatory cytokines regulate the local and 
systemic immune response with release of further cytokines and antibodies. The type of T-
cell response can change the outcome of this infection, as more mucosal damage results 
from T-helper predominant response, whereas a high regulatory T-cell response with 
interleukin-10 release confers gastric ulcer protection (Malfertheiner et al., 2009). 
3.2 Endogenous gastro-protective mediators 
Some endogenous mediators can work through cyto-protective mechanisms reducing 
gastrointestinal injury induced by topical irritants, thus preventing the initial steps of gastric 
inflammation. These endogenous mediators may be inhibited by causative risk factors, 
leading to gastric ulceration and thus provide a mechanism through which these risk factor 
contribute in gastric damage. On the other hand, therapeutic modulation of endogenous 
gastric mediators can provide a target to improve gastric protection against ulceration. 
3.2.1 Mediators of cyclooxygenase pathway: prostaglandins and lipoxins 
Prostaglandins are fatty acids produced from arachidonic acid via cyclooxygenase enzyme. 
It is known that suppression of prostaglandin synthesis is a major mechanism of action of 
aspirin and other non-steroidal anti-inflammatory drugs, which is probably one of the 
mechanisms by which these drugs cause gastric ulcers. Prostaglandins modulate a number 
of components of mucosal defense as they stimulate mucus and bicarbonate secretion, 
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promote mucosal blood flow, increase the resistance of epithelial cells to cytotoxins-induced 
injury and suppress the recruitment of leukocytes into gastric mucosa. Prostaglandins can 
also down regulate the release of a number of other inflammatory mediators that may 
contribute to the generation of gastric ulcer (Martin and Wallace, 2006). Prostaglandin E 
receptors have a prominent role in mucosal protection and gastric ulcer healing (Takeuchi, 
2010). Prostaglandin E2 has been shown to be a potent inhibitor of tumor necrosis factor-ǂ 
and interleukin-1 release from macrophages and of leukotriene B4 and interleukin-8 release 
from neutrophils. 
Lipoxins are the resultant of consequent conversion of arachidonic acid by cyclooxygenase-2 
and 5-lipoxygenase enzymes. Lipoxin-A4 is an endogenous mediator contributing to 
resolution of the inflammatory state and, thus, has an important role in mucosal defense. 
Lipoxin A4 protects the stomach from aspirin-induced damage via suppressing leukocyte 
adherence within gastric micro-circulation. In addition, Lipoxin A4 can inhibit inflammatory 
pain processing and regulate trans-epithelial electrical resistance. Antagonism of Lipoxin A4 
receptor can significantly exacerbate gastric ulcer (Lim et al., 2009). 
3.2.2 Nitric oxide 
Oxidization of arginine by nitric oxide synthase yields the volatile gas nitric oxide, which has 
numerous physiologic properties including regulation of inflammation. Nitric oxide is an 
important factor in modulating gastrointestinal mucosal defense mechanisms. Some of nitric 
oxide actions overlaps with that of prostaglandins, as it modulate the activity of mucosal 
immunocytes and reduce leukocytic endothelial adhesion. In addition, it modulates mucosal 
blood flow and reduces epithelial permeability, resulting in enhanced mucosal resistance to 
ulceration. Nitric oxide also prevents adherence of leukocytes to the vascular endothelium. 
This gaseous mediator has a role also in modulating gastric mucus and bicarbonate secretion. 
Suppression of nitric oxide synthesis renders the gastric mucosa more susceptible to injury, 
while administration of nitric oxide donors can protect the stomach from injury. Agents that 
release nitric oxide in small amounts over a prolonged period have been shown to greatly 
reduce inflammation and to accelerate ulcerative healing (Martin and Wallace, 2006). 
Some studies showed that dietary nitrate and pretreatment with nitric oxide donor 
protected against drug-induced gastric ulcer. Furthermore, the use of nitric oxide-donating 
agents concomitantly with non-steroidal anti-inflammatory drugs as aspirin also resulted in 
reduced risk for gastric ulceration and bleeding. This lead to the development of cyclo-
oxygenase inhibiting/nitric oxide donating drugs, in which nitric oxide is chemically linked 
to a non-steroidal anti-inflammatory drug, which showed effective anti-inflammatory 
capabilities together with less gastric injury. Examples of such drugs include nitric oxide-
flurbiprofen, nitric oxide-ketoprofen, nitric oxide-diclofenac and nitric oxide-naproxen. 
These drugs are suitable therapeutic options for patients with diseases requiring long-term 
non-steroidal anti-inflammatory drugs therapy (Lanas, 2008). 
Despite all evidence that nitric oxide contribute in mediating mucosal defense under normal 
conditions, under different circumstances, as in case of already inflamed mucosa, it is 
suggested that nitric oxide may contribute to tissue injury. In this case, nitric oxide reacts 
with superoxide anion, produced by activated neutrophils, to form peroxynitrite, which is 
another potent oxidant. Peroxynitrite is known to produce widespread gastrointestinal 
injury and inflammation. Although the role of nitric oxide is still controversial, most studies 
suggest a net protective effect of this molecule in the gastrointestinal tract. 
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3.2.3 Hydrogen sulfide 
Hydrogen sulfide is another gaseous mediator generated endogenously that causes 
vasodilatation, decreases adhesion of leukocyte to vascular endothelium, inhibits non-
steroidal anti-inflammatory drugs-induced gastric mucosal injury and inhibit tumor 
necrosis factor-ǂ expression (Tulassay and Herszenyi, 2010). The enzymes responsible for 
hydrogen sulfide generation in the gastric mucosa are cystathionine ǃ-synthase and 
cystathionine Ǆ-lyase. 
Despite the protective role of this gas against mucosal injury, it suspected that hydrogen 
sulphide may contribute to the pro-inflammatory actions in Helicobacter pylori infection. 
Nevertheless, with non-steroidal anti-inflammatory drugs, hydrogen sulfide provide gastric 
protection by inducing up-regulation of anti-inflammatory and cyto-protective genes, 
including hemeoxygenase-1, vascular endothelial growth factor, insulin-like growth factor 
receptor and several genes associated with the transforming growth factor-ǃ receptor 
signaling pathway (Lim et al., 2009). 
A number of therapeutic possibilities combining hydrogen sulfide with non-steroidal anti-
inflammatory drugs are considered in early stages of development. This new class of 
combination is based on that non-steroidal anti-inflammatory drugs reduce hydrogen 
sulphide production in gastric mucosa, which may contribute to these drugs' inducing 
mechanisms of gastric ulcer. In return, sodium hydrogen sulfide prevents the reduction of 
mucosal blood flow induced by non-steroidal anti-inflammatory drugs. Furthermore, this 
gaseous mediator reduces non-steroidal anti-inflammatory drugs-induced leukocyte 
adhesion to vascular endothelial cell. The combination causes reversal of the increased 
expression of tumor necrosis factor-ǂ and improvement prostaglandin E2 synthesis 
impaired by non-steroidal anti-inflammatory drugs (Lim et al., 2009). 
3.2.4 Cytokines 
Cytokines are important in mucosal defense and play a pivotal role in the regulation of the 
mucosal immune system. Interleukin-1ǃ and tumor necrosis factor-ǂ release comprise the 
early inflammatory systemic response to inflammation or infection. Various types of cells 
produce interleukin-1ǃ, including monocytes, macrophages, neutrophils, endothelial cells 
and fibroblasts. Interleukin-1ǃ increases the resistance of gastric mucosa to injury and 
reduces the severity of ulcerative damage. This is through its action as a potent inhibitor of 
gastric acid secretion, stimulator of prostaglandins and nitric oxide release and inhibitor of 
ulcer-promoting mediators as platelet-activating factor from mast cells (Tulassay and 
Herszenyi, 2010). Tumor necrosis factor-ǂ is another key cytokine that contribute in 
producing gastric mucosal injury. Still, by stimulating cell proliferation, tumor necrosis 
factor- may also promote mucosal repair after damage associated with Helicobacter pylori 
infection and the use of non-steroidal anti-inflammatory drugs. Tumor necrosis factor-ǂ 
reverses gastric mucosal injury via stimulation of epithelial cell proliferation. 
3.2.5 Proteinase-activated receptors 
Proteinase-activated-2 receptors are expressed throughout the gastrointestinal tract, 
especially in the epithelial cells and sensory afferent neurons. In the stomach, the activation 
of these receptors triggers mucus secretion and reduces the extent of stomach endothelial 
damage induced by non-steroidal anti-inflammatory drugs. This may be through 
modulating sensory afferent nerves and regulating the release of vascular endothelial 
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growth factor from platelets, which affect new blood vessel angiogenesis that promote ulcer 
healing (Yoshida and Yoshikawa, 2008). 
3.2.6 Proteolytic enzymes 
Proteolytic enzymes have important functions in gastric ulcer prevention and healing. It has 
been shown that impaired fibrinolysis occurs due to alteration of the proteolytic enzymes 
formed through tissue-type plasminogen activator-inhibitor system. Intramucosal proteases; 
as cathepsins, are also involved in protection against gastric ulcer initiation and promotion 
of healing. Cathepsins act as antimicrobial peptides expressed by the gastric epithelium 
preventing bacterial colonization and accelerate ulcer healing. The proteolytic enzymes 
urokinase-type plasminogen activator and plasminogen activator-inhibitor type-1 are 
involved in angiogenesis process, and thus has a direct role in cell proliferation, 
inflammation and ulcer healing. Matrix metalloproteases are involved in extracellular 
matrix reconstitution and tissue remodeling and thus may have an impact in gastric ulcer 
healing (Tomita et al., 2009). Secretory leucocyte protease inhibitor exerts antimicrobial and 
anti-inflammatory effects. Its expression is induced during inflammation. However, the 
expression is significantly decreased during Helicobacter pylori-mediated gastritis. This is 
due to local down-regulation of this proteolytic enzyme in gastric mucosa in response to 
Helicobacter pylori infection (Tulassay and Herszenyi, 2010). 
3.2.7 Heat shock proteins 
Heat shock proteins are important mediators of cellular homeostasis during normal cell 
growth. They also promote cell survival during various cellular stresses, as they are 
generated by gastric epithelial cells in response to oxidative stress, cytotoxicity and high 
temperature. Heat shock proteins generated play an important role in cellular recovery. This 
is done through acting on enzymes related to cyto-protection, gastric inflammation and 
gastric ulcer healing. Heat shock proteins act by refolding these partially damaged 
functional enzymes or increasing delivery of their precursor proteins to important 
organelles such as mitochondria and endoplasmic reticulum. This results in improvement of 
mucosal defense, protection against gastric ulcer and promotion of healing of existing 
damage (Choi et al., 2009). 
3.2.8 Growth factors 
Growth factors are considered a pivotal stimulus for cell proliferation, division, migration 
and re-epithelization. Cell proliferation and repair of injured gastric mucosal epithelium are 
controlled by a number of these growth factors activated as a response to tissue injury. 
Growth factors such as epidermal growth factor, hepatocyte growth factor, platelet derived 
growth factor and basic fibroblast growth factor activate epithelial cell migration and 
proliferation and accelerate ulcer healing by binding to their specific receptors on the cell 
surface, triggering a number of intracellular signaling events that result in cell migration 
and proliferation. 
In the stomach, epidermal growth factor triggers mitogenic response and is important for 
epithelial cell proliferation, migration, re-epithelization and reconstruction of gastric glands. 
Vascular endothelial growth factor is important for angiogenesis, vascular remodeling and 
mucosal regeneration. Transforming growth factor-ǂ protects against gastric mucosal injury 
and promotes wound healing. Receptors for epidermal and transforming growth factors are 
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expressed in gastric progenitor cells and are trans-activated by gastrin and prostaglandin E2 
that trigger cell proliferation and repair of gastric mucosa (Tulassay and Herszenyi, 2010). 
These growth factors are mainly derived from platelets, macrophages and injured tissue. 
Ulceration also triggers induction of genes encoding these growth factors in cells lining 
mucosa of the ulcer margin. These locally produced growth factors activate epithelial cell 
migration and proliferation via actions on autocrine and/or paracrine systems. 
3.2.9 Peroxisome proliferation-activated receptor 
Peroxisome proliferation-activated receptors (ǂ, ǃ and Ǆ) are members of the nuclear 
response family of transcription factors. These receptors are expressed in the gastrointestinal 
tract, liver, skeletal muscle, heart, adipose tissue, breast and skin. Stimulation of peroxisome 
proliferation-activated receptors plays an important role in the mechanism of non-steroidal 
anti-inflammatory drugs action. Peroxisome proliferation-activated receptors cause 
subsequent inhibition of nuclear factor-κB and other transcription factors. These receptors 
regulate transcription of target genes involved in lipid and lipoprotein metabolism, glucose 
homeostasis and cell differentiation. In addition, peroxisome proliferation-activated 
receptors inhibit the activation of certain inflammatory response genes. Thus, activation of 
peroxisome proliferation-activated receptors during non-steroidal anti-inflammatory drugs 
administration blocks the production of inflammatory response markers, such endothelin-1, 
vascular cell adhesion molecule-1 in endothelial cells and tissue factors as matrix 
metalloproteinase-3 and tumor necrosis factor-ǂ in macrophages. These anti-inflammatory 
actions are mediated by inhibition of pro-inflammatory transcription pathways as nuclear 
factor-κB, activator protein-1 and nuclear factor of activated T cells (Lim et al., 2009). 
3.2.10 Neuropeptides 
Several neuropeptides as cholecystokinin, gastrin 17, bombesin, corticotrophin-releasing 
factor, peptide YY and intragastric peptone are involved in gastro-protection. Ghrelin is 
also a neuropeptide associated with gastro-protective effects with important effects on 
energy homeostasis and gastrointestinal motility. Ghrelin is effective against ethanol-
induced gastric ulcers. This protective effect is dependent on cyclooxygenase-1-derived 
prostaglandin E2. Ghrelin mediates its gastro-protective effects also via stimulation of 
nitric oxide production and calcitonin gene related peptide release from sensory afferent 
nerves, enhancing gastric mucosal blood flow. Orexins are another family of 
neuropeptides having gastro-protective role, especially orexin-A. Orexin-A prevents 
mucosal injury and gastric ulceration through several mechanism including increasing 
gastric blood flow, elevating luminal nitric oxide, reducing lipid peroxidation, generating 
prostaglandin E2 and enhancing vagal and sensory nerve activity (Nayeb-Hashemi and 
Kaunitz, 2009). 
3.2.11 Hemeoxygenase-1 enzyme 
Hemeoxygenase-1 is the rate-limiting enzyme of heme catabolism that catalyzes the 
breakdown of heme into carbon monoxide, iron and biliverdin. Hemeoxygenase isoform 1 is 
a phase II drug detoxifying enzyme. It is highly inducible as a response to stress, as 
oxidative stressors, ultraviolet irradiation, inflammatory cytokines, heavy metals and non-
steroidal anti-inflammatory drugs. Up-regulation of hemeoxygenase-1 infers anti-apoptotic 
resistance to the cells due to potent antioxidant effect of bilirubin, biliverdin and carbon 
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monoxide formed. Hemeoxygenase was shown to protect gastric mucosal cells against non-
steroidal anti-inflammatory drugs (Aburaya et al., 2006). 
4. Therapeutic interventions in prevention of gastric ulcer 
Several therapeutic interventions may aid in preventing gastric ulcer. Enhancement of 
normal physical barriers and physiological protective factors can aid in prevention of gastric 
ulcer. Some endogenous gastro-protective factors (see above) may be enhanced to decrease 
the risk of gastric ulcer formation. Conventional medications used in treatment of gastric 
ulcer can also be used in prevention as well, especially in predisposed people. Several 
investigations also tested drugs not conventionally used in treatment of gastric ulcer for 
having possible ulcerogenic protective effects. The main aim of most of these studies is to 
decide which drug to preferentially use in treating conditions presenting concomitantly 
with high risk of development gastric ulcer. 
4.1 Prevention of gastric ulcer by conventional anti-ulcer drugs  
Most anti-ulcer drugs target gastric acid secretion and mucosal defense mechanisms (Table 
1). Successful classes in treating gastric ulcer include Helicobacter pylori eradication 
therapy, prostaglandin analogs, cyto-protective drugs, histamine H2 receptor antagonist and 
proton pump inhibitor groups. In terms of acid inhibition, proton pump inhibitors possess 
higher acid inhibitory potency. Histamine H2 receptor antagonists have, thus, been 
gradually replaced with the more potent class of acid inhibitory drugs, the proton pump 
inhibitors. Current ulcer therapy consists of Helicobacter pylori eradication in Helicobacter 
pylori-positive gastric ulcer and proton pump inhibitors for healing and preventing peptic 
ulcers induced by drugs. 
Proton pump inhibitors selectively block the H+/K+ ATPase of the parietal cells. These 
proton pump inhibitors are the most popular group of drugs used in Helicobacter pylori 
eradication regimens (see before; section 2.1). Misoprostol, a prostaglandin analog, has been 
the most widely used but its application is limited by abdominal side-effects as abdominal 
cramps and diarrhea. Sucralfate and bismuth salts improve mucosal repair. Sucralfate also 
acts by reducing acid secretion and suppressing Helicobacter pylori infection. Bismuth salts, 
having mild anti-Helicobacter pylori activity, are used in treatment of gastric ulcer therapy 
in combination with antibiotics (Malfertheiner et al., 2009). 
All of these drugs have been used successfully to treat gastric ulcers and prevent remittent 
attacks. Nevertheless, their efficiency in prevention of gastric ulcers in individual 
predisposed groups is still controversial. Histamine H2 receptor antagonist is one example, 
as their standard dosage succeeded only in reducing the risk of duodenal ulcer, but not 
gastric ulcer induced by non-steroidal anti-inflammatory drugs. The benefit from histamine 
H2 receptor antagonists was limited to preventing the risk of ulcers induced by Helicobacter 
pylori infection (Chan and Graham, 2004). Contrarily, in another study, histamine H2 
receptor antagonists were effective for prevention of low dose aspirin-induced ulcers and 
showed similar potency as proton pump inhibitors (Nakashima et al., 2009). Another 
example is the use of cyto-protective drugs (as in Table 1) for prevention of gastric ulcer, 
whose efficacy is still controversial. 
Using these conventional anti-ulcer drugs in prevention of gastric ulceration is, thus, 
dependent on the type of predisposing risk factor. Risk factors used in assessment are old 
age, presence of cardiovascular diseases, use of high dose or multiple non-steroidal anti-
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inflammatory drugs, concomitant use of low-dose aspirin and other anti-platelet drugs, 
corticosteroids or warfarin. When one or two of these factors are present, presenting a 
moderate risk, an anti-secretory agent or misoprostol may be used. If three or more risk 
factors are combined, presenting a high risk, switching from non-selective, to selective 
cyclooxygenase inhibitors is recommended. In addition, misoprostol can be used for 
prevention of aspirin- or warfarin-induced gastric ulcers. In very high risk patients, who 
have been subjected to previous ulcer complications, avoidance of non-steroidal anti-
inflammatory drugs and intake of proton pump inhibitor and/or misoprostol is 
recommended. 
 
Drug group Examples Mechanism of action 
Helicobacter pylori 
eradication therapy 
Proton pump inhibitor with 
two antibiotics 
Treatment of Helicobacter 
pylori infection and 
prevention of ulcer 
formation 
Proton pump inhibitors 
 
Omeprazole, pantoprazole, 
lansoprazole, rabeprazole, 
esomeprazole 
Most potent acid inhibition 
Histamine H2 receptor 
antagonists  
 
Cimetidine, ranitidine, 
famotidine, nizatidine, 
roxatidine, lafutidine  
Less potent acid inhibition 
Prostaglandin analogs Misoprostol Weak acid inhibition and 
increase mucosal resistance 
Cyto-protective drugs Rebamipide, azulensulfonate, 
teprenone, polaprezinc, 
sofalcone, alginate sodium 
Very weak effect in cyto-
protection and 
enhancement of natural 
defense mechanisms 
Bismuth salts  
 
Subcitrate, subsalicylate Weak antibacterial effect 
and increase mucosal 
prostaglandin synthesis 
Table 1. Drugs used in prevention and treatment of gastric ulcer and their main 
mechanism(s) of action. 
4.2 Non-conventional gastro-protective drugs 
A number of drugs, other than traditional anti-ulcer medications, were investigated and 
showed an effect in prevention of gastric ulcer formation. Stress causing hypertension may 
concomitantly predispose to gastric ulcer. The effect of antihypertensive drugs, namely 
angiotensin II T1 receptor blocker; telmisartan, was investigated for its effect as gastro-
protective agent. The results showed that telmisartan and candesartan can prevent gastric 
ulcer formation, with higher potency of telmisartan than candesartan. Telmisartan's 
protection of gastric mucosa from non-steroidal anti-inflammatory drugs-induced ulceration 
is possibly through its anti-oxidant action and may also be ascribed, at least in part, to its 
peroxisome proliferator-activated receptor Ǆ agonistic properties (Morsy et al., 2009).  
Gastric ulcer is also commonly seen concurrently in type 2 diabetic patients. Moreover, 
peptic ulcers related to the diabetic state are more severe and are often associated  
with complications. The possible gastro-protective effects of insulin sensitizers 
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thiazolidinediones; rosiglitazone and metformin were tested. Both drugs have the ability to 
ameliorate oxidative stress and inflammation, rendering them attractive candidates for the 
prevention of gastric ulcer in patients with type 2 diabetes. Both rosiglitazone and 
metformin prevented indomethacin-induced gastric ulcer in diabetic rats. Their gastro-
protective effects were probably due to anti-secretory actions, enhanced mucosal protection 
and anti-oxidant activity. This was reflected on their ability to increase mucin concentrations 
and gastric mucosal nitric oxide levels. In addition, rosiglitazone increased gastric juice pH, 
providing superior gastro-protection to metformin (Morsy et al., 2010). 
Other investigations tested the effect of another anti-diabetic drug; pioglitazone as a gastro-
protective drug. Pioglitazone has an agonist of peroxisome proliferator-activated receptor Ǆ 
and exerted strong effect in both preventing the formation of gastric ulcers and healing of 
already existing ones. This gastric ulcer preventing/healing effect of pioglitazone is, at least 
in part, mediated by endogenous nitric oxide. Astonishingly, under diabetic conditions, 
pioglitazone gastro-protective effect decreased. The attenuation of pioglitazone action is 
possibly due to reduction in nitric oxide, angiogenesis and increased expression and release 
of pro-inflammatory cytokines under diabetic conditions (Konturek et al., 2010). 
Organoselenium compounds were tested in naproxen- and Helicobacter pylori-induced 
gastric ulcers and showed not only gastro-protective and ulcer healing effects, but also they 
possessed antibacterial effect against Helicobacter pylori (Santhosh et al., 2010). When tested 
on indomethacin-induced gastric ulcer in mice, melatonin demonstrated gastro-protective 
effects via having angiogenic properties through up-regulation of matrix metalloproteinase-
2; an important regulator of angiogenesis (Ganguly et al., 2010). 
5. Gastric protection by herbs 
 
Herbs
Safer
Cheaper
Less side effects
Drugs
Expensive
Drug interactions
More side effects
 
Fig. 4. Herbs, unlike traditional drugs are natural, safer, cheaper and with less side effects. 
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The need for more effective and cheaper management and prevention of gastric ulcer has 
attracted an increasing interest for herbal products because of their effectiveness, less side 
effects and relatively low costs (Fig. 4). For long, some herbal tea constituents and food 
additives have been known for their gastro-protective effects. For example, liquorice has 
been used as gastro-protective agent. Eugenol, a compound extracted from clove oil, has 
also protective effect against the formation of indomethacin-induced gastric ulcer. This 
effect was mediated by its anti-oxidant activity, decreasing acid-pepsin secretion and 
increasing mucus production (Morsy and Fouad, 2008). 
Similarly, curcumin demonstrated protective effect against gastric ulcer via inhibiting 
gastric acid secretion, relieving oxidative stress and ameliorating apoptosis. A number of 
Chinese naturally occurring phytochemicals were reported to have gastro-protective action 
with potent anti-Helicobacter pylori effects (Li et al., 2005). Lysophosphatidic acid, which is 
a component of soybean lecithin and antyu-san, has a protective effect against gastric ulcer 
induction in an animal model, suggesting that daily intake of lysophosphatidic acid-rich 
foods or Chinese medicines may be beneficial for prevention of gastric ulcer in humans 
(Adachi et al., 2011). In the ongoing search for bioactive natural products of herbal origin 
that have ulcer protective activity, crude plant extracts and plant-derived compounds are 
tried in different experimental models. 
5.1 Herbal extracts 
Several studies on the gastro-protective effect of crude plant extracts have been undertaken. 
Although the pathogenesis of gastric ulcer is multi-factorial, secretion of gastric acid is still 
recognized as a central component of this disease; therefore the main therapeutic target is 
the control of this secretion using the anti-secretory drugs. On the other hand, many plant 
extracts, which significantly decrease the ulcer index in experimental animals, have no 
clinical effects owing to their deficient anti-secretory activity. Accordingly, a large number 
of studies have been addressing the relationship between plant extracts and their anti-
secretory activity on animal experimental models. 
We conducted a PubMed search to identify the most relevant articles to these crude plant 
extracts and focused on those related to the anti-secretory properties, published between 
January 2010 and December 2010. The number of articles retrieved in a search with such 
tight limitations reflected the increased scientific interest in using plant extracts in 
prevention and treatment of gastric ulcer. These natural herbal extracts that has gastro-
protective effect include methanol extract of Abarema cochliacarpos bark, a plant that 
mainly grows in Brazil (da Silva et al., 2010). Another herb, celery (Apium graveolens), 
which is widely used as food additive worldwide, was also tested, and ethanol extracts of it 
showed anti-secretory properties (Al-Howiriny et al., 2010). 
Extracts of herbs that mainly grow and are widely used in India were tested for their gastro-
protective effects as aqueous extract of Pedalium murex leaves (Banji et al., 2010), methanol 
extract of Hedyotis puberula (Joseph et al., 2010), methanol extract of Punica granatum 
(Alam et al., 2010), aqueous extract of Myrtus communis (common myrtle) berries (Sumbul 
et al., 2010), extracts of Cinnamomum tamala leaves (Eswaran et al., 2010) and extracts of 
Xylocarpus granatum fruit (Lakshmi et al., 2010). Roxb (Ailanthus excelsa bark) 
(Melanchauski et al., 2010) and camelthorn (Alhagi maurorum) (Shaker et al., 2010) that are 
widely used in Egypt also showed gastro-protection against ulcers. Hot water extract of 
Trichosanthes cucumerina Linn that is mainly used in Sri Lanka also showed similar effects 
(Arawwawala et al., 2010). 
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5.2 Pure compounds 
Purified compounds may have the privilege of specifying the exact compound that is 
exerting gastro-protective effects. Unlike total herbal extract, pure compounds may lack the 
presence of several combined components that may contradict each other's action or add an 
undesired adverse effect. 
5.2.1 Flavonoids 
Flavonoids represent a highly diverse class of secondary metabolites that constitute the 
largest and most important group of polyphenolic compounds in plants. The pleiotropic 
actions of natural compounds are important for developing new drugs for multifactorial 
diseases. This is particularly true with regards to flavonoids as they display several 
pharmacological properties in the gastro-protective area, acting as anti-secretory, cyto-
protective and antioxidant agents. Besides their action as gastro-protective, flavonoids also 
can be alternatives for suppression or modulation of gastric ulcers associated with 
Helicobacter pylori. Flavonoid fraction extracted from Mouriri pusa leaves, a plant from 
Brazilian cerrado also known as manapuçá or jaboticaba do mato which is commonly used 
in the treatment of gastrointestinal disturbs in its native region, shows beneficial effects in 
prevention and reversal of gastric ulcer (Vasconcelos et al., 2010). 
Quercetin has an anti-secretory mechanism of action. It has antihistaminic properties, 
therefore, decreases histamine levels, as well as preventing the release of histamine from 
gastric mast cells and inhibiting the gastric H+/K+ proton pump, diminishing acid gastric 
secretion. On the other hand, the gastro-protective effects of chalcones involve increasing 
the mucosal blood flow, stimulating the synthesis of mucus in the gastric mucosa and 
increasing prostaglandin levels. Nevertheless, the most important mechanism of action 
responsible for the anti-ulcer activity of flavonoids is their antioxidant properties, seen in 
garcinol, rutin and quercetin, which involve free radical scavenging, transition metal ions 
chelation, inhibition of oxidizing enzymes, increase of proteic and nonproteic antioxidants 
and reduction of lipid peroxidation. In addition, sofalcone (a chalcone) and quercetin 
(flavonol) have anti-Helicobacter pylori activity (Mota et al., 2009). 
5.2.2 Alkaloids 
Alkaloids represent a diverse group of low molecular weight nitrogen-containing secondary 
metabolites that have gastro-protective activity. For examples, the isoquinoline alkaloid 
isolated from Coptidis rhizome, coptisine; the quinolizidine alkaloid isolated from Sophora 
flavescens, matrine which decreases the acid secretion and inhibits the gastric motility; the 
piperidine alkaloid piperine, which protects the stomach against ulceration by decreasing 
the volume of gastric juice, gastric acidity and pepsin-A activity; the phenylakylamide 
alkaloid capsaicin, which inhibits the acid secretion, stimulates the alkali/mucus secretions 
and mainly increases the gastric mucosal blood flow; the steroidal alkaloid pachysandrine A 
obtained from Pachysandra terminalis; and the indole alkaloid nigakinone found in 
Picrasma quassioides, which decreases gastric acid/pepsin secretions and protects the 
mucous membrane (de Sousa et al., 2008). 
5.2.3 Terpenoids 
Terpenoids are a large and diverse class of naturally-occurring organic chemicals similar to 
terpenes. Gastro-protective terpenoids have been isolated from several plants, including 
www.intechopen.com
 
Prevention of Gastric Ulcers 
 
457 
sesquiterpenes from Artemisa douglasiana, triterpenes from Fabiana imbricate and 
carbenoxolone from Glycyrrhiza glabra. Most of the work on the gastro-protective activity 
has been focused on the clerodane diterpenes from Croton cajucara. Other diterpenes with 
anti-ulcerogenic effect include cordatin from Aparisthmium cordatum and trichorabdal A 
from Rabdosia trichocarpa (Schmeda-Hirschmann and Yesilada, 2005). 
6. Conclusion 
Gastric ulcer is a multi-factorial disease that has become a real socio-economic burden and 
opposes a great challenge in its treatment. Prevention is better than cure, as they say. Usage 
of medications designed for treatment of gastric ulcer as a means for its prevention is faced 
by several drawbacks; as limited effectiveness of these drugs in ulcer prevention, numerous 
side effects of available anti-ulcer drugs and the cost of gastric ulcer medications. 
Consequently, separate line of research has been devoted to investigate preventive measures 
of gastric ulcer. Despite of the size of investigations done on this subject, prevention of 
gastric ulcer is still a challenge especially in predisposed groups. Herbal compounds can 
provide an alternative preventive means for gastric ulcer as they are safer, cheaper and 
usually having limited, if any, side effects. For reaching the optimal remedy that can prevent 
gastric ulcer formation, more investigations are definitely still needed. 
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